Here, we found that DOKD contributed to the up-regulation of S100a9, IL-17, NF-κB p65, TLR4, MyD88, and TNF-α expression, and the down-regulation of HIF-1α expression, suggesting that DOKD may effectively reduce the growth of CT26+ tumor cells through the IL-17/HIF-1α/TLR4/NF-κB p65 signaling pathway. The gene discussed is DDX53; the disease is neoplasm.